Ming Tan

List of Publications by Year
in descending order

105 papers	5,605 citations	76196 40 h-index	82410 72 g-index
110 all docs	110 docs citations	110 times ranked	2727 citing authors

#	Article	IF	Citations
1	Bioengineered pseudovirus nanoparticles displaying the HA1 antigens of influenza viruses for enhanced immunogenicity. Nano Research, 2022, 15, 4181-4190.	5.8	5
2	Quantitative norovirus viral load is not affected by home storage of stool. Transplant Infectious Disease, 2022, 24, .	0.7	2
3	Effects of rotavirus NSP4 protein on the immune response and protection of the SR69A-VP8* nanoparticle rotavirus vaccine. Vaccine, 2021, 39, 263-271.	1.7	15
4	Genetic susceptibility to rotavirus infection in Chinese children: a population-based caseâ€“control study. Human Vaccines and Immunotherapeutics, 2021, 17, 1803-1810.	1.4	7
5	A Nanoparticle-Based Trivalent Vaccine Targeting the Glycan Binding VP8* Domains of Rotaviruses. Viruses, 2021, 13, 72.	1.5	12
6	Characterization of Functional Components in Bovine Colostrum That Inhibit Norovirus Capsid Protruding Domains Interacting with HBGA Ligands. Pathogens, 2021, 10, 857.	1.2	2
7	Prevalence and Evolution of Noroviruses between 1966 and 2019, Implications for Vaccine Design. Pathogens, 2021, 10, 1012.	1.2	6
8	Structural basis of P[II] rotavirus evolution and host ranges under selection of histo-blood group antigens. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	9
9	Intra-species sialic acid polymorphism in humans: a common niche for influenza and coronavirus pandemics?. Emerging Microbes and Infections, 2021, 10, 1191-1199.	3.0	7
10	Norovirus Vaccines: Current Clinical Development and Challenges. Pathogens, 2021, 10, 1641.	1.2	32
11	Structural Basis of Glycan Recognition in Globally Predominant Human P[8] Rotavirus. Virologica Sinica, 2020, 35, 156-170.	1.2	19
12	Molecular basis of P[II] major human rotavirus VP8* domain recognition of histo-blood group antigens. PLoS Pathogens, 2020, 16, e1008386.	2.1	25
13	Histo-blood group antigens as divergent factors of groups A and C rotaviruses circulating in humans and different animal species. Emerging Microbes and Infections, 2020, 9, 1609-1617.	3.0	5
14	Epidemiology and HBGA-susceptibility investigation of a G9P[8] rotavirus outbreak in a school in Lechang, China. Archives of Virology, 2020, 165, 1311-1320.	0.9	3
15	Title is missing!. , 2020, 16, e1008386.		0
16	Title is missing!. , 2020, 16, e1008386.		0
17	Title is missing!. , 2020, 16, e1008386.		0
18	Title is missing!. , 2020, 16, e1008386.		0

#	Article	IF	Citations
19	GII.13/21 Noroviruses Recognize Glycans with a Terminal Î²-Galactose via an Unconventional Glycan Binding Site. Journal of Virology, 2019, 93, .	1.5	8
20	Parenterally Administered P24-VP8* Nanoparticle Vaccine Conferred Strong Protection against Rotavirus Diarrhea and Virus Shedding in Gnotobiotic Pigs. Vaccines, 2019, 7, 177.	2.1	16
21	Structural basis of host ligand specificity change of GII porcine noroviruses from their closely related GII human noroviruses. Emerging Microbes and Infections, 2019, 8, 1642-1657.	3.0	5
22	Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development. Pharmaceutics, 2019, 11, 472.	2.0	22
23	Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice. Vaccine, 2019, 37, 4103-4110.	1.7	18
24	Structural Adaptations of Norovirus GII.17/13/21 Lineage through Two Distinct Evolutionary Paths. Journal of Virology, 2019, 93, .	1.5	16
25	Genetic Analysis of Reemerging GII.P16-GII.2 Noroviruses in 2016â€“2017 in China. Journal of Infectious Diseases, 2018, 218, 133-143.	1.9	43
26	Human Group C Rotavirus VP8*s Recognize Type A Histo-Blood Group Antigens as Ligands. Journal of Virology, 2018, 92, .	1.5	21
27	Quantifying the binding stoichiometry and affinity of histo-blood group antigen oligosaccharides for human noroviruses. Glycobiology, 2018, 28, 488-498.	1.3	14
28	Saliva as a source of reagent to study human susceptibility to avian influenza H7N9 virus infection. Emerging Microbes and Infections, 2018, 7, 1-10.	3.0	8
29	Bioengineered Norovirus S₆₀ Nanoparticles as a Multifunctional Vaccine Platform. ACS Nano, 2018, 12, 10665-10682.	7.3	28
30	Comparison of the efficacy of a commercial inactivated influenza A/H1N1/pdm09 virus (pH1N1) vaccine and two experimental M2e-based vaccines against pH1N1 challenge in the growing pig model. PLoS ONE, 2018, 13, e0191739.	1.1	3
31	Histo-blood group antigens as receptors for rotavirus, new understanding on rotavirus epidemiology and vaccine strategy. Emerging Microbes and Infections, 2017, 6, 1-8.	3.0	64
32	Human intestinal organoids express histo-blood group antigens, bind norovirus VLPs, and support limited norovirus replication. Scientific Reports, 2017, 7, 12621.	1.6	42
33	Characterization of Antigenic Relatedness between GII.4 and GII.17 Noroviruses by Use of Serum Samples from Norovirus-Infected Patients. Journal of Clinical Microbiology, 2017, 55, 3366-3373.	1.8	19
34	Recent advancements in combination subunit vaccine development. Human Vaccines and Immunotherapeutics, 2017, 13, 180-185.	1.4	32
35	Norovirus GII.17 Natural Infections in Rhesus Monkeys, China. Emerging Infectious Diseases, 2017, 23, 316-319.	2.0	16
36	Structural basis of glycan specificity of P[19] VP8*: Implications for rotavirus zoonosis and evolution. PLoS Pathogens, 2017, 13, e1006707.	2.1	38

#	Article	IF	Citations
37	Glycan Specificity of P[19] Rotavirus and Comparison with Those of Related P Genotypes. Journal of Virology, 2016, 90, 9983-9996.	1.5	46
38	Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus. Scientific Reports, 2016, 6, 25735.	1.6	23
39	Complete Genome Sequence of a GII.17 Norovirus Isolated from a Rhesus Monkey in China. Genome Announcements, 2016, 4, .	0.8	3
40	P[8] and P[4] Rotavirus Infection Associated with Secretor Phenotypes Among Children in South China. Scientific Reports, 2016, 6, 34591.	1.6	37
41	A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus. Vaccine, 2016, 34, 905-913.	1.7	32
42	Characterization of the new GII.17 norovirus variant that emerged recently as the predominant strain in China. Journal of General Virology, 2016, 97, 2620-2632.	1.3	44
43	An outbreak caused by GII.17 norovirus with a wide spectrum of HBGA-associated susceptibility. Scientific Reports, 2015, 5, 17687.	1.6	64
44	Tulane virus recognizes sialic acids as cellular receptors. Scientific Reports, 2015, 5, 11784.	1.6	33
45	A Unique Human Norovirus Lineage with a Distinct HBGA Binding Interface. PLoS Pathogens, 2015, 11, e1005025.	2.1	42
46	Tulane Virus Recognizes the A Type 3 and B Histo-Blood Group Antigens. Journal of Virology, 2015, 89, 1419-1427.	1.5	43
47	Affinities of human histo-blood group antigens for norovirus capsid protein complexes. Glycobiology, 2015, 25, 170-180.	1.3	23
48	Strain-specific interaction of a GII.10 Norovirus with HBGAs. Virology, 2015, 476, 386-394.	1.1	17
49	Crystal structures of GI.8 Boxer virusÂP dimers in complex with HBGAs, a novel evolutionary path selected by the Lewis epitope. Protein and Cell, 2015, 6, 101-116.	4.8	15
50	Antigenic Relatedness of Norovirus GII.4 Variants Determined by Human Challenge Sera. PLoS ONE, 2015, 10, e0124945.	1.1	15
51	Vaccine against norovirus. Human Vaccines and Immunotherapeutics, 2014, 10, 1449-1456.	1.4	27
52	Histo-blood group antigens: a common niche for norovirus and rotavirus. Expert Reviews in Molecular Medicine, 2014, 16, e5.	1.6	133
53	Identifying Carbohydrate Ligands of a Norovirus P Particle using a Catch and Release Electrospray Ionization Mass Spectrometry Assay. Journal of the American Society for Mass Spectrometry, 2014, 25, 111-119.	1.2	22
54	A dual vaccine candidate against norovirus and hepatitis E virus. Vaccine, 2014, 32, 445-452.	1.7	35

#	Article	IF	Citations
55	Intranasal P Particle Vaccine Provided Partial Cross-Variant Protection against Human GII.4 Norovirus Diarrhea in Gnotobiotic Pigs. Journal of Virology, 2014, 88, 9728-9743.	1.5	47
56	Branched-linear and agglomerate protein polymers as vaccine platforms. Biomaterials, 2014, 35, 8427-8438.	5.7	18
57	Gangliosides are Ligands for Human Noroviruses. Journal of the American Chemical Society, 2014, 136, 12631-12637.	6.6	56
58	Subviral particle as vaccine and vaccine platform. Current Opinion in Virology, 2014, 6, 24-33.	2.6	35
59	Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age. Journal of General Virology, 2013, 94, 2005-2016.	1.3	51
60	A dual chicken IgY against rotavirus and norovirus. Antiviral Research, 2013, 97, 293-300.	1.9	35
61	Polyvalent complexes for vaccine development. Biomaterials, 2013, 34, 4480-4492.	5.7	39
62	Norovirus P Particle Efficiently Elicits Innate, Humoral and Cellular Immunity. PLoS ONE, 2013, 8, e63269.	1.1	60
63	Affinities of recombinant norovirus P dimers for human blood group antigens. Glycobiology, 2013, 23, 276-285.	1.3	34
64	Inhibition of Histo-blood Group Antigen Binding as a Novel Strategy to Block Norovirus Infections. PLoS ONE, 2013, 8, e69379.	1.1	39
65	Cryo-EM Structure of a Novel Calicivirus, Tulane Virus. PLoS ONE, 2013, 8, e59817.	1.1	28
66	Two Gastroenteritis Outbreaks Caused by GII Noroviruses: Host Susceptibility and HBGA Phenotypes. PLoS ONE, 2013, 8, e58605.	1.1	24
67	Poly-LacNAc as an Age-Specific Ligand for Rotavirus P[11] in Neonates and Infants. PLoS ONE, 2013, 8, e78113.	1.1	53
68	Rotavirus VP8*: Phylogeny, Host Range, and Interaction with Histo-Blood Group Antigens. Journal of Virology, 2012, 86, 9899-9910.	1.5	152
69	Spike Protein VP8* of Human Rotavirus Recognizes Histo-Blood Group Antigens in a Type-Specific Manner. Journal of Virology, 2012, 86, 4833-4843.	1.5	221
70	Evaluation of anti-norovirus IgY from egg yolk of chickens immunized with norovirus P particles. Journal of Virological Methods, 2012, 186, 126-131.	1.0	32
71	Structure, stability and dynamics of norovirus P domain derived protein complexes studied by native mass spectrometry. Journal of Structural Biology, 2012, 177, 273-282.	1.3	48
72	Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus. Nanomedicine, 2012, 7, 889-897.	1.7	72

#	Article	IF	Citations
73	Tannic acid inhibited norovirus binding to HBGA receptors, a study of 50 Chinese medicinal herbs. Bioorganic and Medicinal Chemistry, 2012, 20, 1616-1623.	1.4	52
74	The formation of P particle increased immunogenicity of norovirus P protein. Immunology, 2012, 136, 28-29.	2.0	10
75	Norovirus P Particle, a Novel Platform for Vaccine Development and Antibody Production. Journal of Virology, 2011, 85, 753-764.	1.5	135
76	A candidate dual vaccine against influenza and noroviruses. Vaccine, 2011, 29, 7670-7677.	1.7	57
77	Norovirusâ€"host interaction: Multi-selections by human histo-blood group antigens. Trends in Microbiology, 2011, 19, 382-388.	3.5	143
78	Norovirus P Particle as a Platform for Antigen Presentation. Procedia in Vaccinology, 2011, 4, 19-26.	0.4	23
79	Genetic diversity of noroviruses in Chinese adults: Potential recombination hotspots and GII-4/Den Haag-specific mutations at a putative epitope. Infection, Genetics and Evolution, 2011, 11, 1716-1726.	1.0	14
80	Terminal modifications of norovirus P domain resulted in a new type of subviral particles, the small P particles. Virology, 2011, 410, 345-352.	1.1	53
81	Crystallography of a Lewis-Binding Norovirus, Elucidation of Strain-Specificity to the Polymorphic Human Histo-Blood Group Antigens. PLoS Pathogens, 2011, 7, e1002152.	2.1	97
82	Genetic and Phenotypic Characterization of GII-4 Noroviruses That Circulated during 1987 to 2008. Journal of Virology, 2010, 84, 9595-9607.	1.5	61
83	Norovirus Gastroenteritis, Carbohydrate Receptors, and Animal Models. PLoS Pathogens, 2010, 6, e1000983.	2.1	172
84	Molecular Pathogenesis of Human Norovirus. , 2009, , 575-600.		3
85	Conservation of Carbohydrate Binding Interfaces â€" Evidence of Human HBGA Selection in Norovirus Evolution. PLoS ONE, 2009, 4, e5058.	1.1	103
86	Outbreak studies of a GIIâ€3 and a GIIâ€4 norovirus revealed an association between HBGA phenotypes and viral infection. Journal of Medical Virology, 2008, 80, 1296-1301.	2.5	115
87	Emergence of the GII4/2006b variant and recombinant noroviruses in China. Journal of Medical Virology, 2008, 80, 1997-2004.	2.5	59
88	Elucidation of strain-specific interaction of a GII-4 norovirus with HBGA receptors by site-directed mutagenesis study. Virology, 2008, 379, 324-334.	1.1	71
89	Noroviral P particle: Structure, function and applications in virusâ€"host interaction. Virology, 2008, 382, 115-123.	1.1	137
90	Structural Basis for the Receptor Binding Specificity of Norwalk Virus. Journal of Virology, 2008, 82, 5340-5347.	1.5	145

#	Article	IF	Citations
91	Association of Histoâ€"Blood Group Antigens with Susceptibility to Norovirus Infection May Be Strainâ€Specific Rather than Genogroup Dependent. Journal of Infectious Diseases, 2008, 198, 940-941.	1.9	23
92	Norovirus gastroenteritis, increased understanding and future antiviral options. Current Opinion in Investigational Drugs, 2008, 9, 146-51.	2.3	16
93	Structural Basis for the Recognition of Blood Group Trisaccharides by Norovirus. Journal of Virology, 2007, 81, 5949-5957.	1.5	332
94	Norovirusâ€"host interaction: implications for disease control and prevention. Expert Reviews in Molecular Medicine, 2007, 9, 1-22.	1.6	98
95	C-Terminal Arginine Cluster Is Essential for Receptor Binding of Norovirus Capsid Protein. Journal of Virology, 2006, 80, 7322-7331.	1.5	56
96	The P Domain of Norovirus Capsid Protein Forms a Subviral Particle That Binds to Histo-Blood Group Antigen Receptors. Journal of Virology, 2005, 79, 14017-14030.	1.5	188
97	Norovirus and Histo-Blood Group Antigens: Demonstration of a Wide Spectrum of Strain Specificities and Classification of Two Major Binding Groups among Multiple Binding Patterns. Journal of Virology, 2005, 79, 6714-6722.	1.5	366
98	Norovirus and its histo-blood group antigen receptors: an answer to a historical puzzle. Trends in Microbiology, 2005, 13, 285-293.	3.5	280
99	Human Milk Contains Elements That Block Binding of Noroviruses to Human Histoâ€"Blood Group Antigens in Saliva. Journal of Infectious Diseases, 2004, 190, 1850-1859.	1.9	84
100	E. coli-expressed recombinant norovirus capsid proteins maintain authentic antigenicity and receptor binding capability. Journal of Medical Virology, 2004, 74, 641-649.	2.5	69
101	The P Domain of Norovirus Capsid Protein Forms Dimer and Binds to Histo-Blood Group Antigen Receptors. Journal of Virology, 2004, 78, 6233-6242.	1.5	202
102	Mutations within the P2 Domain of Norovirus Capsid Affect Binding to Human Histo-Blood Group Antigens: Evidence for a Binding Pocket. Journal of Virology, 2003, 77, 12562-12571.	1.5	171
103	Norovirus Gastroenteritis. , 0, , 39-52.		0
104	Bovine natural antibody <scp>IgM</scp> inhibits the binding of human norovirus protruding domain to its <scp>HBGA</scp> receptors. FEBS Open Bio, 0, , .	1.0	0
105	Structural Insight into Terminal Galactose Recognition by Two Non-HBGA Binding GI.3 Noroviruses. Journal of Virology, 0, , .	1.5	0